Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
National Presto Industries reported a significant increase in net earnings for the nine months ended October 4, 2026, reaching $42.5 million compared to $18.1 million in the prior year period. This growth was driven by a 20.6% increase in net sales to $409.6 million and improved gross profit margins, alongside a $1.7 million gain from the sale of property, plant, and equipment.
AB Private Lending Fund reported a net increase in net assets resulting from operations of $8.86 million for the nine months ended September 30, 2026, compared to $9.22 million in the prior year period. Total investment income grew to $25.86 million, though net investment income per share decreased from $1.86 to $1.69 due to a higher weighted average share count.
First National Corp reported net income of $1.25 per share for both the third quarter and the first nine months of 2026. The company maintained stable dividend payouts and saw a slight increase in total assets compared to the prior year-end, supported by growth in interest and fees on loans.
Enveric Biosciences reported financial results for the third quarter of 2026 and provided a corporate update on its lead candidate EB-003. The company is completing final IND-enabling activities for EB-003, a non-hallucinogenic neuroplastogenic candidate, with plans for an IND submission and Phase 1 clinical trial.
Term
Q3 2026
“Our focus during the third quarter was advancing final IND-enabling activities for EB-003 as we prepare for the planned IND submission and first-in-human Phase 1 clinical trial of our lead non-hallucinogenic, neuroplastogenic candidate.”
Joseph Tucker, Ph.D., Chief Executive Officer of Enveric
“The growing body of preclinical evidence reinforces our confidence in this opportunity as we complete the final IND-enabling activities and prepare to advance EB-003 toward first-in-human clinical development.”
Joseph Tucker, Ph.D., Chief Executive Officer of Enveric
Aptera Motors reported a GAAP net loss of $14.0 million for the third quarter of 2026, with research and development spending more than doubling year-over-year. The company ended the quarter with $9.2 million in cash and highlighted a new strategic partnership with Shanghai Launch Automotive Technology to support manufacturing and contract engineering.
Term
Q3 2026
“In the third quarter we started the process of procuring parts for our first production vehicles. We also entered into a strategic partnership with Launch to support manufacturing and contract engineering, which we believe has helped lower our estimated capital needs to reach start of production and, most importantly, the capital we estimate is required to reach a production rate at which we believe we could fund ongoing operations from vehicle sales.”
SenesTech, Inc. reported a net loss of $5.85 million for the nine months ended September 30, 2026, compared to $4.58 million in the prior year period, despite a 31% increase in total revenues to $2.36 million. The company's cash position decreased to $3.95 million, and management indicated that current resources are only sufficient to fund operations for approximately nine months from the filing date.
For the nine months ended September 30, 2026, the WisdomTree Bitcoin Fund reported a net decrease in net assets resulting from operations of $1,601,685, primarily driven by a net change in unrealized depreciation on bitcoin. Despite the operational loss, net assets grew to $171.9 million from $139.7 million at the start of the year, bolstered by $33.9 million in net capital share transactions.
Amesite Inc. reported a net loss of $774,395 for the quarter ended September 30, 2026, compared to a loss of $642,266 in the prior year period, driven by increased technology and content development costs. The company's management expressed substantial doubt about its ability to continue as a going concern, noting that current cash reserves may not sustain operations for the next twelve months.
The Morgan Stanley Bitcoin Trust commenced operations on April 7, 2026, and reported net assets of $873.4 million as of September 30, 2026. For the period from inception through September 30, 2026, the Trust saw a net increase in net assets from operations of $96.6 million, primarily driven by $97.5 million in unrealized appreciation on its bitcoin holdings.
High Roller Technologies reported a net loss of $7.1 million for the nine months ended September 30, 2026, compared to a net loss of $0.2 million in the prior year period. Revenues decreased significantly from $15.8 million to $8.6 million year-over-year, while the company successfully completed an offering that increased cash and cash equivalents to $13.4 million.
Carlyle Credit Solutions reported total investment income of $66.7 million for the quarter ended September 30, 2026, and net investment income of $38.3 million. Total net assets decreased slightly to $1.74 billion from $1.77 billion at year-end 2025, primarily driven by $51.7 million in net unrealized depreciation on investments and $129.7 million in distributions to stockholders.
AmperCap Acquisition Co's 10-Q filing for the period ending September 30, 2026, reflects its status as a blank check company with no current operations. The report details administrative expenses and interest income generated from the trust account as the company continues to evaluate potential business combination targets. No definitive merger agreements or significant changes in financial guidance were disclosed.
TRex Bio reported financial results for the third quarter of 2026, highlighting a net loss of $14.1 million and a cash position of $154.2 million. The company recently completed a $133.5 million IPO in October 2026, which extends its expected cash runway into the second half of 2029 to support its clinical pipeline, including TRB-061 and TRB-071.
Term
Q3 2026
“The positive Phase 1a results for TRB-061 demonstrated selective activation and expansion of immunoregulatory Tregs in humans, providing clinical evidence that we believe supports this approach. We are now focused on understanding whether these effects can translate into meaningful and durable disease control for patients with atopic dermatitis.”
Johnston Erwin, Chief Executive Officer of TRexBio
“With the completion of our IPO, we have the resources to advance TRB-061 toward its planned mid-2027 clinical readout and expect to bring TRB-071, which targets a distinct Treg pathway, into the clinic in the first half of 2027.”
Johnston Erwin, Chief Executive Officer of TRexBio
IRulya Therapeutics Inc. significantly strengthened its liquidity position in the first nine months of 2026, with cash and short-term investments increasing to $105.2 million from $17.8 million at year-end 2025. The company underwent a major restructuring of its balance sheet, eliminating over $100 million in total liabilities and issuing Series C Preferred Stock valued at $143.8 million following the acquisition of Orphai Therapeutics.
Propanc Biopharma reported a net loss of $8.6 million for the quarter ended September 30, 2026, compared to a $4.8 million loss in the prior year, driven largely by a significant increase in compensation and professional expenses. The company's cash position decreased to $258,366 from $832,006 at the start of the fiscal year, though it raised $2 million through the exercise of Series C warrants.
Air Industries Group reported a significant turnaround in the third quarter of 2026, with net sales increasing to $14.6 million and net income reaching $946,000 compared to a loss in the prior year period. However, for the nine months ended September 30, 2026, the company still recorded a net loss of $920,000 despite a 8.7% increase in year-to-date net sales.
Siebert Financial Corp. reported a net loss of $3.0 million for the nine months ended September 30, 2026, compared to a net income of $5.6 million in the prior year period. While total revenue grew to $79.3 million, expenses surged to $83.7 million, driven by higher employee compensation, technology costs, and one-time settlement and impairment charges.
SilverBox Corp IV reported a net income of $3.64 million for the nine months ended September 30, 2026, primarily driven by $4.77 million in interest earned on trust account investments. During the period, the company experienced significant redemptions, with $207.5 million withdrawn from the Trust Account, leaving $10.64 million in investments remaining.
BioKey (Cayman), Inc. reported zero revenue for the nine months ended September 30, 2026, with a net loss of $873,721 compared to $538,188 in the prior year period. The company remains heavily dependent on recurring loans from ABVC BioPharma, Inc. to support its operations, with total liabilities reaching $7.56 million against total assets of $1.61 million.
Arrive AI Inc. reported a net loss of $24.1 million for the nine months ended September 30, 2026, compared to a $10.1 million loss in the prior year period, driven largely by a $12.3 million loss on the conversion of notes. Total assets decreased to $9.2 million from $10.9 million at year-end 2025, while the company maintained a stockholders' equity of $2.2 million.
Planet Green Holdings Corp. reported a significant increase in net revenues to $9.58 million for the nine months ended September 30, 2026, compared to $67,270 in the prior year, though it still incurred a net loss of $1.04 million. The company's balance sheet shows a total stockholders' deficit of $3.06 million, and it continues to manage significant liabilities from discontinued operations.
CCS IX Portfolio Holdings, LLC reported a significant increase in total investment income to $58.6 million for the nine months ended September 30, 2026, compared to $18.5 million in the prior year period. Net assets grew to $732.4 million, driven by $353.3 million in capital contributions and $31.6 million in net increase in net assets from operations.
Dyadic International reported a net loss of $5.4 million for the nine months ended September 30, 2026, compared to $5.8 million in the prior year. The company is undergoing a strategic rebranding to Dyadic Applied BioSolutions, shifting focus from research to commercialized protein production platforms across life sciences and food sectors.
Saga Communications reported a net loss of $7.1 million for the third quarter of 2026, primarily driven by a $9.2 million impairment of intangible assets. Net operating revenue decreased to $26.7 million from $28.2 million in the prior year period, while total assets declined to $183.0 million as of September 30, 2026.
Waterstone Financial, Inc. reported net income of $20.6 million for the nine months ended September 30, 2026, an increase from $18.7 million in the prior year period. The company experienced a decrease in total assets to $2.25 billion, primarily driven by a reduction in loans held for sale and cash equivalents, while net interest income improved due to lower interest expenses on deposits and borrowings.
Spectral Capital Corporation reported a significant revenue increase to $865.9 million for the nine months ended September 30, 2026, compared to $3.1 million in the prior year, primarily driven by business combinations. Despite the revenue growth, the company realized a net loss of $5.4 million for the period due to high cost of revenues and increased operating expenses.
PMGC Holdings Inc. reported a significant revenue increase to $4.52 million for the nine months ended September 30, 2026, compared to $0.29 million in the prior year. However, net loss widened to $10.15 million due to increased operating expenses and interest costs, while the company underwent a series of reverse stock splits totaling 1-for-240.
Waterstone Financial reported Q3 2026 net income of $6.2 million, or $0.36 per diluted share, down from $7.9 million in the prior year quarter. The Community Banking segment achieved record quarterly net interest income of $16.0 million, while the Mortgage Banking segment faced a pre-tax loss of $754,000 due to rising mortgage rates and compressed sales margins.
Term
Q3 2026
“We are pleased with the hard work to reach another strong quarter with increased challenges from rising short-term and long-term treasury rates. The Community Banking segment realized another record quarterly net interest income of $16.0 million, which represented a $1.4 million increase compared to the quarter ended September 30, 2025.”
William Bruss, Chief Executive Officer of Waterstone Financial, Inc.
Actuate Therapeutics reported a net loss of $13.9 million for the nine months ended September 30, 2026, compared to $17.7 million in the prior year period. The company's cash position decreased significantly to $2.1 million, resulting in a working capital deficit and a stated going concern uncertainty as it continues to fund clinical development of elraglusib.
Stemtech Corp reported a significant decline in net sales to $1.37 million for the nine months ended September 30, 2026, compared to $2.42 million in the prior year period. The company continues to operate at a loss, with a net loss of $1.93 million for the first nine months of 2026 and a total stockholders' deficit of $8.38 million.